T-Cell Therapies in the Real World
Time: 9:00 am
day: Day 1
Details:
- Data supporting FDA approval of afamitresgene autoleucel, the first engineered T-cell therapy for solid tumors, targeting unresectable or metastatic synovial sarcoma
- Optimizing the regulatory process throughout development, and paving the way for future cell therapies
- Data from the IGNYTE ESO trial with letetresgene autoleucel for the treatment of synovial sarcoma and myxoid/round cell liposarcoma (MRCLS)
